The purpose of this paper is to provide the rationale for therapeutic silencing of the alpha-synuclein gene (SNCA) in Parkinson’s disease (PD). The paper reviews the public health significance of PD; the causal links between rare SNCA variants and familial PD; the association of common SNCA variants and PD susceptibility; the association of SNCA variants also with age at onset and motor and cognitive outcomes in PD; therapeutic strategies targeting SNCA in PD; and preliminary findings and considerations on small interfering RNA-based therapies and PD.

Citations

Citations to this article as recorded by  

• Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera
  Yuquan Tong, Peiyuan Zhang, Xueyi Yang, Xiaohui Liu, Jie Zhang, Magda Grudniewska, Ikrak Jung, Daniel Abegg, Jun Liu, Jessica L. Childs-Disney, Quentin M. R. Gibaut, Hafeez S. Haniff, Alexander Adibekian, M. Maral Mouradian, Matthew D. Disney
  Proceedings of the National Academy of Sciences.2024;[Epub]     CrossRef
• Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments
  Ankita Wal, Pranay Wal, Himangi Vig, Nem Kumar Jain, Shruti Rathore, Karthickeyan Krishnan, Ashish Srivastava
  Current Drug Discovery Technologies.2023;[Epub]     CrossRef
• Antisense therapies in neurological diseases
  Jean-Baptiste Brunet de Courssou, Alexandra Durr, David Adams, Jean-Christophe Corvol, Louise-Laure Mariani
  Brain.2022; 145(3): 816.     CrossRef
• Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
  L. Ma, M. Gholam Azad, M. Dharmasivam, V. Richardson, R.J. Quinn, Y. Feng, D.L. Pountney, K.F. Tonissen, G.D. Mellick, I. Yanatori, D.R. Richardson
  Redox Biology.2021; 41: 101896.     CrossRef
• Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA
  Peiyuan Zhang, Hye-Jin Park, Jie Zhang, Eunsung Junn, Ryan J. Andrews, Sai Pradeep Velagapudi, Daniel Abegg, Kamalakannan Vishnu, Matthew G. Costales, Jessica L. Childs-Disney, Alexander Adibekian, Walter N. Moss, M. Maral Mouradian, Matthew D. Disney
  Proceedings of the National Academy of Sciences.2020; 117(3): 1457.     CrossRef
• Small molecule recognition of disease-relevant RNA structures
  Samantha M. Meyer, Christopher C. Williams, Yoshihiro Akahori, Toru Tanaka, Haruo Aikawa, Yuquan Tong, Jessica L. Childs-Disney, Matthew D. Disney
  Chemical Society Reviews.2020; 49(19): 7167.     CrossRef
• Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease
  Yun Joong Kim, Junbeom Jeon, Jaemoon Shin, Nan Young Kim, Jeong Hoon Hong, Jae‐Min Oh, SangKyoon Hong, Yeo Jin Kim, Young‐Eun Kim, Suk Yun Kang, Hyeo‐Il Ma, Unjoo Lee, Jeehee Yoon
  Movement Disorders.2017; 32(8): 1211.     CrossRef
• Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy
  Michele Schlich, Francesca Longhena, Gaia Faustini, Caitriona M. O’Driscoll, Chiara Sinico, Anna Maria Fadda, Arianna Bellucci, Francesco Lai
  Nano Research.2017; 10(10): 3496.     CrossRef
• Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
  Elvira Valera, Brian Spencer, Eliezer Masliah
  Neurotherapeutics.2016; 13(1): 179.     CrossRef
• RETRACTED: Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders
  Hayate Javed, Sindhu A Menon, Karima M Al-Mansoori, Abdelmojib Al-Wandi, Nour K Majbour, Mustafa T Ardah, Shiji Varghese, Nishant N Vaikath, M Emdadul Haque, Mimoun Azzouz, Omar MA El-Agnaf
  Molecular Therapy.2016; 24(4): 746.     CrossRef